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Background: At present, there is little information in Bulgaria regarding the rate and stability of frequent-exacerbation phenotype in COPD patients. Aim: To study the rate and stability of frequent-exacerbation phenotype in COPD patients. Materials and methods: We followed up 465 COPD patients for exacerbations over a 3-year period. Exacerbations were defi ned as events that resulted in treatment with antibiotics and/or corticosteroids (moderate), or that led to hospitalization (severe).
Result: Approximately 10% of the patients had two or more exacerbations per year (frequent-exacerbation phenotype), and this structure stayed stable over the study period. The exacerbation rate in the fi rst year of follow up was 0.33 per stage I COPD patients (according to GOLD stages), 0.49 per stage II COPD patients; 0.69 -for stage III, and 1.06 for stage IV COPD patients. The frequent-exacerbation rate increased from stage I to stage IV by 4.35%, 9.17%, 10.79%, and 20.97%, respectively. A history of previous year exacerbations increased the risk of new exacerbations: with a history of one exacerbation -OR 2.1820 (95% CI: 1.4018 to 3.3965, p = 0.0005), and with a history of two exacerbations -OR 4.6460 (95% CI: 2.3286 to 9.2696; p < 0.0001). The frequent-exacerbation phenotype appeared to be unstable over the study period -up to 33% from those patients stayed in the phenotype for the next year.
Conclusions:
The exacerbation frequency and the rate of frequent-exacerbation phenotype increases with COPD progression. History of exacerbations in the previous year is a signifi cant risk factor for exacerbations of COPD. The frequent-exacerbation phenotype appeared to be unstable over the study period. The phenotype of non-exacerbators was more likely to remain stable over time.
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a common disease of considerable social impact, with an increasing effect on morbidity, disability and mortality. About one in ten people suffer from COPD. 1 Globally, it has been estimated that about three million people die of COPD every year. 2 Exacerbations are important events in the natural course of COPD and are related to worsening of respiratory symptoms. They increase the use of medication, healthcare costs and mortality. Exacerbations also lead to unscheduled medical visits and hospitalizations. 3 The relation between exacerbation frequency and the disease severity has been studied. 4 Frequent exacerbations are related to faster decline of lung function, 5 lower quality of live, 6 decreased physical capacity 7 and increased local and systemic infl ammation 8 . Patients with frequent exacerbations were also found to have shorter time to the next exacerbation. 9 According to some studies, the number of exacerbations in the previous year is the best predictor for future exacerbations. 10, 12 Seemungal et al. used the term 'frequent exacerbators' for COPD patients with three or more exacerbations per year. They found that these patients had a worse quality of life compared to patients with two or less exacerbations per year. 5 The GOLD committee has accepted and published 11 the defi nition of frequent exacerbator phenotype used by Hurst et al. (two or more exacerbations per year). According to their study, this phenotype was stable over time. 12 On the other hand, a primary care study estimated the tendency for COPD patients to remain in the same GOLD category over time. They found that the majority of patients in GOLD group D moved to less severe groups within 12 months. This change was due to decrease in exacerbation frequency, while FEV1 was relatively stable over the years of reevaluation. 13 Another study showed that as much as 24% of the patients the researchers followed changed their original group in one year -17% of the infrequent exacerbators became frequent exacerbators while 39% of the frequent exacerbators became infrequent ones. Up to 57% of the frequent exacerbators changed the group in two years, but the factors associated with this were understudied. 7 This data raise the question about the stability of the frequent exacerbator phenotype over time.
AIM
To study the frequent exacerbator phenotype in COPD patients and its stability over time.
MATERIALS AND METHODS

STUDY DESIGN AND PATIENTS
Seven pulmonologists took part in the study. A group of consecutive COPD patients (n=465) signed informed consent and were followed up prospectively for three year. The Research Ethics Committee of the Medical University of Pleven approved the study.
COPD was diagnosed by the pulmonologists according to the Global Initiative for Chronic Obstructive Lung Disease 2011 (GOLD) criteria. 11 The inclusion criteria were post bronchodilator obstruction defi ned as FEV1/FVC<0.70 and age of more than 40 years. At baseline visits, patients underwent spirometry 15 minutes after administration of 400 μg of salbutamol, and completed a specially designed study card which obtained information about the medical history, smoking status, occupation and medication of the patients. All patients fi lled in two questionnaires -CAT and mMRC. After the initial visit, the patients were followed up every 6 months.
STUDY OUTCOMES
Exacerbations of COPD (AECOPD) were the primary outcome. All exacerbations were confi rmed by pulmonologists. Exacerbation was defi ned as acute worsening of the patient's respiratory symptoms from the stable state that required treatment with antibiotic and/or systemic glucocorticosteroids (moderate) or hospitalization (severe). 11 Severe exacerbations were the ones that required hospitalization while moderate exacerbations were treated in the ambulatory settings with antibiotics and/or corticosteroids. The exacerbation was considered a new event if the onset was at least 28 days after discontinuation of medication for a previous exacerbation. If it was diagnosed within the 28-day window the new event was considered as a relapse and not included in the estimation of exacerbations frequency, as recommended by Burge and Wedzicha. 14 This defi nition is considered valid in epidemiological studies. 15, 16 The data about mortality was collected from a national database. The causes for death were not confi rmed by autopsies. The data about patients' characteristics is shown in Table 1 .
STATISTICAL ANALYSIS
Statistical analysis was performed with Statgraphics plus v.2.1. Descriptive data are reported as means ±SD or percentages, as appropriate. The exacerbations were evaluated as a number per person per year. Differences in exacerbations between groups were analyzed using a nonparametric Kruskal-Wallis test. After the fi rst year of follow-up, exacerbations were analyzed as an indicator variable (a patient has one, two or more, or no exacerbation during the study year one). We defi ned frequent exacerbations as two or more exacerbations in a year according to GOLD 2011 criteria. 11 A signifi cance threshold of <0.05 was used to determine the qualifi cation of data.
RESULTS
A total of 465 unselected COPD patients were enrolled in the study. We identifi ed 685 AECOPD during the follow up period. The main characteristics of the patients are shown in Table 1 . Their distribution in groups according to the number of exacerbations during the fi rst year of follow up are: 8.82% (n=41) had ≥2 exacerbations (frequent exacerbators); 30.90% (n=153) had 1 exacerbation (infrequent exacerbators); 50.75% (n=236) had no exacerbations (non-exacerbators) and 7.53% (n=35) died.
FACTORS ASSOCIATED WITH EXACERBATION HISTORY
Comorbidities were found to differ signifi cantly between the groups according to the number of exacerbations during the study year one. Frequent exacerbators were found to have more cardiologic, respiratory, gastrointestinal and nephrological concomitant diseases compared to patients with no exacerbations during the fi rst year of the study. Infrequent exacerbators also were found to have more cardiologic, respiratory and gastrointestinal coexisting diseases compared to those patients. The only medical condition that was found to differ signifi cantly between frequent and infrequent exacerbator groups was arterial hypertension. The result are shown in Table 2 . Severity of obstruction was associated with exacerbation history. The groups of exacerbators (both frequent and infrequent) included up to 56.78% of patients with severe and very severe obstruction, which was signifi cantly higher than the group of non-exacerbators in the study year one -31.45% (p< 0.0001) (95% CI; 16.0866 to 34.1354; χ 2 30.185; DF 1). The mean FEV1 in the exacerbator groups was 45.85%±19.05 for frequent exacerbators, 48.6%±20.09 for infrequent exacerbators. Both were lower than in patients with no exacerbations -58.96±18.33 (p<0.05).
THE IMPACT OF EXACERBATION HISTORY ON EXACER-BATION RATE
To evaluate the role of exacerbation history on exacerbation rate, we assessed exacerbation rate in the second study year in patients with history of frequent, infrequent, and no exacerbations in preceding year (study year one). We found that exacerbation rates for study year 2 were respectively 1.05, 0.63, and 0.28 per patient per year for frequent exacerbators, infrequent exacerbators and non-exacerbators from study year one. All these differences were statistically signifi cant at p<0.05. We estimated that history for one moderate or severe exacerbation in the previous year increased the risk of having at least one exacerbation per year -OR 2.1820 p<0.0005. A history of two and more exacerbations increased this risk additionally -OR 4.6460 (p<0.0001) (Fig. 1) .
The importance of exacerbation history led to 
STABILITY OF FREQUENT EXACERBATOR PHENOTYPE
The overall structure of these unselected COPD patients during the follow up period is shown in Fig. 2 .
We found that between 8.8% and 9.8% of all COPD patients had frequent exacerbations every year.
Of 430 patients who survived the fi rst year of the study, 236 (50.75%) had no exacerbations. 170 of them had no exacerbations in study year 2 (negative predictive value 72.03%). From those patients with no history of AECOPD in two consequent years (n=170), 124 had no exacerbations in study year 3 (negative predictive value 72.91%).
Frequent exacerbators from the fi rst study year were 41 (8.82%) and 10 of them were found to be frequent exacerbators in study year two (positive predictive value 24.39%). At least one exacerbation was found in 58.54% (n=24) of them in study year two.
From all patients that had survived the second year of the study, we found 43 frequent exacerbators and 13 of them had frequent exacerbations in year 3 (positive predictive value 30.23%). We followed the patients with frequent exacerbations both in study years 1 and 2 (n=10). We found that only 3 of them had frequent exacerbations in year 3.
The stability of exacerbation frequency is shown in Fig. 3 .
DISCUSSION
During the fi rst year of the study, we found that 50.75% of the COPD cohort had no moderate or severe exacerbations and up to 8.82% had two or more exacerbations (frequent exacerbators). The exacerbations were not normally distributed among COPD patients as shown before. 17 This result could be partly explained by the differences in comorbidities between the groups. Coexisting cardiovascular diseases have already been found to increase the risk of severe AECOPD. 18 We also found that some gastrointestinal diseases were associated with increased frequency of exacerbations. This supports the data from the ECLIPSE study where gastroesophageal refl ux disease (GЕRD) was associated with the AECOPD frequency. 12 Patients with a coexisting respiratory disease are often excluded from COPD clinical trials. 19 In our study we found that 6.24% (n=29) of COPD patients in our region had post tuberculosis pneumofi brosis and 4.95% (n=23) had bronchiectasis. These factors were associated with a history of frequent exacerbations (p<0.05). A study from Turkey has shown that a history of tuberculosis has an impact on the rate of severe exacerbations of COPD. 20 A possible underlying mechanism is bacterial lower respiratory tract colonization of these patients, which is a known risk factor for frequent exacerbations. 21, 22 We found that the frequency of exacerbations increases with decline of obstruction. Exacerbators had lower FEV1 compared to non-exacerbators. This data supports a systematic review of 37 studies, which also found such an association. 23 History of exacerbations had an impact on exacerbation rate. In the second year of the study, we found an exacerbation rate of 1.05, 0.63 and 0.28 per patient per year for frequent, infrequent and non-exacerbators, respectively. We found a signifi cantly increased risk for an exacerbation in year one -OR 2.1820 (p<0.0005) and OR 4.6460 (p<0.0001) for patients with one and two or more exacerbations, respectively, compared to patients with no exacerbations. This data is in concordance with other studies. 12, 24, 25 As long as some patients were in group GOLD D (GOLD 2011) only because of frequent exacerbations and other, only because of the severity of obstruction, we suspected the presence of inhomogeneity in exacerbation risk within this group. We found signifi cantly increased exacerbation rate for two consecutive years in patients GOLD D and frequent exacerbations in the fi rst year of the study, compared to patients GOLD D and no exacerbations. The risk of one or more moderate to severe AECOPD in one year for those patients was higher (OR 3.5118, p=0.0006). This inhomogeneity in exacerbation risk for COPD patients GOLD D is supported by other studies 26, 27 and led to a new revision of GOLD in 2017 11 .
A history of frequent exacerbations seems to be 
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very important in predicting exacerbation risk and COPD course. On the other hand, there is a limited number of studies which followed the stability of the frequent exacerbator phenotype. GOLD accepted its presence based only on the data reported by Hurst et al. 12 To estimate the frequency of AECOPD we should differ two separate exacerbations. We used a threshold of 28 days after recovery of a previous exacerbation based on a large systematic review by Burge and Wedzicha. 14 They recommended events of worsening of respiratory symptoms consistent with AECOPD defi nition up to 28 days after fi nishing treatment for previous exacerbation to be called relapse. These relapses may be due to a new peak of bacterial load 14 days after viral AECOPD studied by George et al. 28 In their study, Hurst at al. defi ne distinct exacerbations as events that started minimum seven days after the end of a prior episode (recovery being defi ned by the patient). 12 This may lead to overestimation of exacerbation frequency.
In our study, non-exacerbators stayed relatively * The fi gure shows the exacerbation rate among 465 unselected COPD patients for three years. ** The sum of per cent of all is less than 100% because of excluded patients due to death in years 1 and 2.
stable over the time -up to 74% of them had no exacerbations during next year. This data is consistent with that reported by Hurst et al. 12 Infrequent exacerbators have a higher risk of AECOPD in one year. Between 33% and 37% of them had at least one moderate to severe exacerbation. However, most of them (55% -57%) have no exacerbation. In contrast, Hurst et al. found that 83% from infrequent exacerbators had at least one exacerbation in one year. 12 Frequent exacerbators have the highest risk of exacerbation compared to other groups. Most of them had at least one exacerbation in the second year of the study -between 58% and 80%. However, less than 33% of them kept exacerbating frequently during the following year. Our results differ signifi cantly from the study of Hurst et al. who found that 60% of frequent exacerbators had two or more AECOPD in one year. 12 A study from Spain showed that 49.8% of frequent exacerbators had at least one exacerbation during the following year. Unfortunately, the authors did not show the rate of frequent exacerbators. 29 Another nationwide register-based study showed that only six percent of frequent exacerbators stay in this category for fi ve years. 30 This data shows the need to reconsider the defi nition and stability of the frequent exacerbator phenotype.
There is a lack of prospective studies about the stability of the phenotype of frequent exacerbators.
STRENGTHS AND POTENTIAL LIMITATIONS OF THE STUDY
This is a real-life study which shows the frequency of moderate to severe exacerbations among unselected COPD patients. All exacerbations are diagnosed and treated by pulmonologists. Unfortunately, we were unable to estimate mild exacerbations. The rate of frequent exacerbators among unselected COPD patients is relatively low -so far, we have followed up only a small number of them. A long-term prospective study to defi ne this phenotype is perhaps needed.
CONCLUSION
History of a COPD exacerbation is an important factor that is related to exacerbation rate. Frequent exacerbators are at higher risk for future AECOPD. 
